Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

Memorial Sloan Kettering Cancer Center20 enrolled

Overview

The researchers are doing this study to test the ability of a new technology called breathprinting, or electronic nose (E-Nose), to measure how people respond to standard treatment for malignant pleural mesothelioma (MPM). The researchers will study how E-Nose breathprints change over time as people receive standard treatment for MPM. They will also look at how changes in people's E-Nose breathprints compare to changes in their standard imaging scans and in biomarkers of MPM in their blood.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Malignant Pleural Mesothelioma

Interventions

E-Nose testing

At baseline (before any treatment is administered) approximately when the patient is scheduled for a CT of the Chest and/or PET/CT after initiation of any treatment, as medically permissible and at the PI's discretion. A breath sample from each patient will be captured in a cartridge, which will form the basis for the E-Nose analysis, to be performed by study investigators at UCB.

Research bloodDIAGNOSTIC_TEST

Research blood tests will be obtained at baseline and the first three standard of care follow up visits, scheduled by their treating physician along with a CT of the Chest and/or PET/CT1 to determine whether serum biomarkers of MPM.

Eligibility

Sex: ALLMin age: 30 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Aged 30-85 years * No history of thoracic cancer or extrathoracic cancer potentially involving pleural metastases (i.e., breast, gastric, colon, or pancreas cancer) * Recent diagnosis of MPM * Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study, and signed standard surgical consent for surgical resection Exclusion Criteria: * Aged \<30 or \>85 years at the first outpatient visit * History of thoracic or extrathoracic cancer that puts the subject at risk for pleural or pulmonary metastases

Locations (7)

Memorial Sloan Kettering Basking Ridge (Consent Only)

Basking Ridge, New Jersey, United States

RECRUITING

Memorial Sloan Kettering Monmouth (Consent Only)

Middletown, New Jersey, United States

RECRUITING

Memorial Sloan Kettering Bergen (Consent Only )

Montvale, New Jersey, United States

RECRUITING

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent Only)

Commack, New York, United States

RECRUITING

Memorial Sloan Kettering Westchester (Consent Only)

Harrison, New York, United States

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, United States

RECRUITING

Memorial Sloan Kettering Nassau (Consent Only)

Uniondale, New York, United States

RECRUITING

Central Contacts

Gaetano Rocco, MD

CONTACT

212-639-3478 roccog@mskcc.org

David Jones, MD

CONTACT

212-639-6428

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

Overview

Conditions

Interventions

Eligibility

Locations (7)

Outcomes

Primary Outcomes

Central Contacts